Atorvastatin Calcium Tablets, 20 mg*, packaged in a) 90-count bottles (NDC 0378-3951-09) and b) 5...

FDA Drug Recall #D-0619-2017 — Class II — March 20, 2017

Recall Summary

Recall Number D-0619-2017
Classification Class II — Moderate risk
Date Initiated March 20, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mylan Pharmaceuticals Inc.
Location Morgantown, WV
Product Type Drugs
Quantity 299,112 bottles

Product Description

Atorvastatin Calcium Tablets, 20 mg*, packaged in a) 90-count bottles (NDC 0378-3951-09) and b) 500-count bottles (NDC 0378-3951-07); Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.

Reason for Recall

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Distribution Pattern

Nationwide in the USA and Puerto Rico

Lot / Code Information

Lot #: a) 3073776, Exp 01/18; 3073777, 3074909, Exp 02/18; 3075564, 3075565, Exp 03/18; 2007338, Exp 08/18; b) 3070838, Exp 10/17; 3073775, Exp 01/18; 3074908, 3074909, Exp 02/18; 3075564, Exp 03/18; 2007224, 3075887, Exp 06/18; 2007337, 2007338, Exp 08/18

Other Recalls from Mylan Pharmaceuticals Inc.

Recall # Classification Product Date
D-0049-2021 Class III Candesartan Cilexetil and Hydrochlorothiazide T... Oct 2, 2020
D-1057-2020 Class III Tacrolimus Capsules, USP 5mg, 100-count bottle,... Mar 23, 2020
D-1031-2020 Class II Sotalol HCL Tablets, USP (AF) 80 mg, 100 count ... Mar 9, 2020
D-0791-2020 Class II Nizatidine Capsules, USP 150 mg, Rx Only, Mylan... Jan 7, 2020
D-0792-2020 Class II Nizatidine Capsules, USP 300 mg, Rx Only, Mylan... Jan 7, 2020

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.